ClinicalTrials.gg
RecruitingNCT07859111Updated Oct 5, 2026

YJ001 Spray for Diabetic Peripheral Neuropathic Pain

A Phase 3 interventional study of YJ001 spray simulant and YJ001 spray in Diabetic Peripheral Neuropathic Pain (DPNP), sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.

Planned enrollment
2nd of 30
400 · median 158
Started
2026
with 3 others
Phase 3
5 of 40
1 open now
Primary completion
2028-08
later than 14 of 15 live
Registered
39th of 40
by date

Among the 40 studies in Neuralgia with a site in China, this one is the 2nd largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 39th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if YJ001 Spray works to treat diabetic patients with Diabetic Peripheral Neuropathic Pain..It will also learn about the safety of drug YJ001 Spray.This trial is divided into two parts. The first part of the trial is designed as a randomized, double-blind, double-dummy, parallel-controlled, multi-center clinical trial with positive reference product and placebo; the second part is designed as a single-arm, open-label, multi-center clinical trial.In the first part, the trial was divided into the test group, the positive control group, and the placebo group.

In the first part,The experimental group received YJ001 spray + clobazam besylate capsule placebo, the positive control group received YJ001 spray placebo + clobazam besylate capsule, and the placebo group received YJ001 spray placebo + clobazam besylate capsule placebo. In the second part, all participants were treated with the investigational product, and 30 trial participants underwent PK blood sample collection according to the protocol.

Part I of the trial : To evaluate the efficacy and safety of YJ001 spray in treating diabetic peripheral neuropathic pain.

Part 2 of the trial: Evaluate the long-term efficacy and the pharmacokinetic characteristics of YJ001 spray in treating dia betic peripheral neuropathic pain at the clinically recommended dosage.

Participants will:

Apply spray topically to both feet twice daily, with six sprays per foot at each administration.

Visit the clinic once every 1 or 2 or 4 weeks for checkups and tests Complete a study diary daily to record pain intensity, sleep interference, study-drug administration, and spray-related respiratory irritation.

03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain (DPNP)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years, of either gender
  • Diagnosed with type 1 or type 2 diabetes for at least 1 year
  • Diagnosed with diabetic peripheral neuropathic pain (DPNP, other tertiary hospitals' diagnostic certificates are acceptable), with pain duration ≥6 months, and the most painful area being the foot
  • Stable blood glucose control within 3 months prior to screening, i.e., (HbA1c) ≤9.0% at screening. If the patient has been receiving hypoglycemic drug treatment at screening, stable treatment for at least 30 days is required;
  • If the patient has been receiving neurotrophic, circulation-improving, and metabolic drug treatments at screening, stable dosing for at least 30 days is required. If the patient has discontinued neurotrophic, circulation-improving, and metabolic drug treatments at screening, the duration of drug withdrawal must meet at least 7 drug half-lives as determined by the investigator;
  • If the patient has been receiving non-pharmacological treatments (including physiotherapy, massage, chiropractic treatment, psychological therapy, etc.) at screening, stable treatment for at least 12 weeks is required, and the treatment regimen must not be changed during the trial
  • If the patient has not been receiving stable non-pharmacological treatments (including physiotherapy, massage, chiropractic treatment, psychological therapy, etc.), non-pharmacological treatment must be discontinued for at least 1 week prior to screening, and no additional non-pharmacological treatments are planned to be added during the trial
  • Pain NRS score ≥4.0 and \<9.0 at screening
  • After the run-in period and before randomization, the trial participant meets all inclusion criteria and does not meet any exclusion criteria
  • The ADPS score during the run-in period [defined as the average of the daily pain NRS scores calculated based on the patient diary card records excluding the day of randomization] is ≥4, and the trial participant completes at least 10 pain assessments during the run-in period (excluding the day of randomization); - Both pain VAS scores at screening and during the 2-day visit before randomization are ≥40mm and \<90mm
  • Medication adherence to the study drug during the run-in period is 80-120% (inclusive)
  • The trial participant is willing and able to adhere to study visit schedules, treatment plans, laboratory tests, and other research procedures, agrees to participate in this trial, and signs a written form.

Participants in the second part of the trial must meet all the following criteria to be eligible for enrollment in the second part of this study.

  • Trial participants who have completed the double-blind treatment period;
  • Trial participants who are willing and capable of adhering to the study visit schedule, treatment plan, laboratory tests, and other research procedures.

Exclusion criteria

Exclusion Criteria:

Experiment Part One

  • Known or suspected to be allergic to or have serious adverse reactions to the active ingredients of Kligabalin Benzenesulfonate Capsules or any ingredients, or allergic to or have serious adverse reactions to the ingredients of YJ001 Spray, the ingredients of YJ001 Spray Simulant, paracetamol, aspirin, salicylic acid or similar drugs of YJ001 (such as 5-aminosalicylic acid, sulfasalazine and salicylate);
  • Previous use of calcium channel modulators such as pregabalin, gabapentin, krigabalin, and melogabalin without improvement in pain (reported by the patient);
  • Those who have participated in the clinical study of YJ001 spray and received the study drug in the past;
  • According to the research, the test participants are in the acute stage of diabetes peripheral neuropathic pain, or need surgery for focal compression neuropathy, or have widespread systemic pain that will affect the evaluation of pain at the drug delivery site. According to the judgment of the researchers, the evaluation of pain at the drug delivery site will be affected; Or more severe in the hands or closer areas than in the feet; Or the test participants have pain caused by non diabetes peripheral neuropathy, such as active osteoarthritis, lumbar disc herniation, vitamin B deficiency (vitamin B12, folic acid), alcoholism, herpetic neuralgia, vasculitis, and serious depression, anxiety and other psychological diseases, which will affect the researchers' evaluation of diabetes peripheral neuropathic pain;
  • Participants who have severe peripheral vascular disease (such as intermittent claudication and lower limb arterial occlusion) during screening and are deemed unsuitable by the researchers to participate in the trial;
  • Abnormal skin conditions at the site of administration can affect the determination of test results, such as:

    1. Those with a skin condition evaluation score greater than 2 points at the site of administration;
    2. There is skin disease in the affected skin area, which affects the investigator's evaluation of diabetes related peripheral neuropathic pain, or the skin at the administration site is red, swollen, inflamed, damaged or other conditions that affect drug absorption, or according to the investigator's judgment, the test participants have tattoos that may interfere with the research purpose;
    3. Patients with foot ulcers, infections and gangrene related to diabetes that have not recovered.
  • Malignant tumor patients, except for non skin basal cell carcinoma or squamous cell carcinoma that has received appropriate treatment or resection, or cervical cancer in situ;
  • Amputation of limbs other than the tips of fingers and toes;
  • Complicated with acute metabolic complications of diabetes, such as diabetes ketoacidosis or lactic acidosis or hyperosmolar hyperglycemia syndrome or diabetes hyperosmolar coma;
  • Within the 6 months prior to screening or during the introduction period, there has been one or more severe hypoglycemic events (referring to trial participants requiring assistance from others to obtain carbohydrates, glucagon, or other rescue measures);
  • When comparing and screening, the ADPS scores of the experimental participants during the introduction period decreased by ≥ 30%; When comparing and screening, the VAS scores of the trial participants decreased by ≥ 30% during the first 2 days of random visits;
  • Those who have been used within 2 weeks before screening or need to be combined with the following treatments during the planned trial: 1) transcutaneous electrical nerve stimulation (TENS), acupuncture and moxibustion treatment, infrared ray, laser, etc; 2) Local analgesics (such as NSAIDs, peppermint ointment, capsaicin patch, lidocaine patch, etc.) and opioid analgesics (such as morphine, tramadol, etc.);
  • During the trial period, it is planned to add and combine non pharmacological treatments such as physical therapy, massage, spinal acupressure therapy, psychological therapy, etc;
  • Before screening, within 7 drug half lives [14 hours for oral ibuprofen tablets and diclofenac sodium tablets, 5 days for naproxen tablets; 2 days for pregabalin capsules and gabapentin tablets, 7 days for krigabalin, 7 days for melogabalin, 4 days for carbamazepine; 2 days for venlafaxine tablets, 4 days for duloxetine, 12 days for amitriptyline, 2 weeks for traditional Chinese medicine], have received analgesic drugs [such as oral NSAIDs, calcium channel modulators (pregabalin, gabapentin, krigabalin, melogabalin) Participants in the trial of SNRIs drugs (such as duloxetine, venlafaxine, etc.), tricyclic antidepressants (such as amitriptyline, etc.), carbamazepine, oxcarbazepine, traditional Chinese medicine, etc.), or those who purchase and use the above drugs themselves during the trial, or those who need to add and use the above analgesic drugs for treatment during the trial (except for Clegabalin);
  • During screening, test participants were associated with the following active infections with abnormal clinical significance, including (HBV), (HCV), syphilis, and (HIV):

Active hepatitis B is defined as: hepatitis B surface antigen positive and HBV-DNA detection value exceeding the ; Active hepatitis C is defined as: positive hepatitis C antibodies and HCV-RNA detection values exceeding the upper limit of normal; Positive for Treponema pallidum antibody (TP Ab) and positive for syphilis non-specific antibody titers; Known as a human immunodeficiency virus infection, or HIV antibody test result positive.

  • Abnormal liver and kidney function during screening: or ALT ≥ 2.5 times the upper limit of normal value, creatinine ≥ 1.5 times the upper limit of normal value; Or accompanied by thyroid dysfunction that cannot be controlled with stable drug doses, or abnormalities in thyroid function test results during screening that require treatment initiation; Or combined with severe cardiovascular and cerebrovascular diseases (such as grade II or III heart block, heart failure classified as III-IV, myocardial infarction, acute stroke, etc.), unstable diseases (such as cerebral infarction, acute coronary syndrome), severe respiratory, blood and hematopoietic system diseases;
  • Those who have suicidal behaviors or suicidal tendencies in the past, or who are complicated with pernicious anemia, untreated hypothyroidism, or have other nervous system diseases (such as cognitive impairment), the researchers think that it may affect the evaluation of diabetes related peripheral neuropathic pain or affect the self rating, or the mental patients who are judged by the researchers to be not suitable for this trial;
  • Known history of drug abuse, drug dependence, and/or alcohol abuse within the past year [drinking more than 14 servings per week (1 serving is equivalent to 360mL of beer, 45mL of 40% alcohol strong liquor, or 150mL of wine)]; 19.Pregnant and lactating women; Male trial participants (including their female partners) and female trial participants with fertility, who have planned to have children or cannot guarantee the use of one or more measures (commonly used contraceptive measures include sterilization surgery, intrauterine devices, birth control pills, condoms, etc.) within 3 months after the end of the trial from screening;
  • During the trial period, participants engaged in driving, operating complex machinery, or other potentially hazardous activities; 21.For patients with a bipedal administration area of less than 450cm\^2[bipedal administration area (cm2)=0.00718 × W \^ 0.425 × H \^ 0.725 × 5% × 10000, where W is weight (kg) and H is height (cm)];
  • Screening participants who have participated in other interventional clinical trials within the previous 3 months;
  • Researchers believe that other situations are not suitable for participation in this experiment.

The second part of the experiment

  • Medication adherence \< 80% or > 120% in double-blind studies;
  • Major safety issues occur in the double-blind study or there are unresolved serious adverse events before the medication administration in the second part of this study;
  • Pregnant and lactating women; male trial participants (including their female partners) and female trial participants who are capable of reproduction, and who intend to conceive or cannot ensure the use of one or more contraceptive measures (common contraceptive measures include sterilization surgery, intrauterine devices, contraceptive pills, condoms, etc.) from the screening phase until 3 months after the end of the trial;
  • Other situations where the researcher deems it inappropriate to participate in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
400 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Drug: YJ001 spray simulant · Drug: Crisugabalin Besilate Capsules simulant

  • Experimental
    experimental group

    Drug: YJ001 spray · Drug: Crisugabalin Besilate Capsules simulant

  • Active comparator
    positive control group

    Drug: YJ001 spray simulant · Drug: Crisugabalin Besilate Capsules

Interventions

  • spray:0 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.

  • spray:480 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.

  • DrugCrisugabalin Besilate Capsules

    capsule:20mg per dose, twice a day

  • DrugCrisugabalin Besilate Capsules simulant

    0mg per dose, twice a day

06

What researchers measure

Primary outcomes

  1. Change from baseline in Average Daily Pain Score (ADPS)

    Change from baseline in Average Daily Pain Score (ADPS). ADPS is collected from patient daily pain diary. The difference between YJ001 spray group and placebo group will be compared.

    Time frame: Week 12

  2. Number of participants with clinically significant changes in safety parameters from baseline

    Safety parameters including adverse events (AEs), laboratory tests, physical examination, vital signs and electrocardiogram (ECG). Clinically significant changes from baseline will be assessed at Week 52 during the open-label extension part (part two).

    Time frame: week 52

Secondary outcomes

  1. Compared with the placebo group, the Change from baseline in Average Daily Pain Score (ADPS) at weeks 1-11 and 13 after treatment in the test group

    ADPS is collected from the average daily pain NRA score based on diary card records. The difference between YJ001 spray group and placebo group will be compared

    Time frame: weeks 1-11 and 13

  2. Compared with the positive control group, the change in Average Daily Pain Score(ADPS) from baseline to the 1-13 weeks after treatment in the test group;

    ADPS is collected from the average daily pain NRA score based on diary card records.

    Time frame: weeks 1-13

  3. The response rates of ADPS (the proportion of trial participants with weekly ADPS decrease of ≥30% and ≥50% relative to baseline) in the three groups at the 12 and 13 week after treatment

    Time frame: weeks 12 and 13

  4. The proportion of trial participants with ADPS scores less than 1 in the three groups at the 12 and 13 weeks after treatment

    Time frame: 12 and 13 weeks

  5. Change from baseline in Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS) score

    Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain. Change from baseline in SF-MPQ-VAS scores will be compared among the three groups at Week 12 and Week 13.

    Time frame: 12th and 13th weeks

  6. Change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) total score

    Short-Form McGill Pain Questionnaire (SF-MPQ). Total score ranges from 0 to 45. Higher scores indicate worse pain. Change from baseline in SF-MPQ total scores will be compared among the three groups at Week 12 and Week 13.

    Time frame: 12th and 13th weeks

  7. At the 13th week after treatment, the overall impression of pain change (PGIC) among the three groups of trial participants

    Patient Global Impression of Change (PGIC). The scale ranges from 1 to 7. Lower scores indicate better improvement in pain. PGIC scores will be compared among the three groups at Week 13.

    Time frame: 13th week

  8. Changes in weekly average sleep disturbance scores from baseline at weeks 12 and 13 after treatment in the three groups

    Weekly average sleep disturbance score. The scale ranges from 0 to 10. Higher scores indicate worse sleep disturbance. Change from baseline in weekly average sleep disturbance scores will be compared among the three groups at Week 12 and Week 13.

    Time frame: weeks 12 and 13

  9. Changes in Hospital Anxiety and Depression Scale (HADS) scores from baseline at the 12th and 13th weeks after treatment in the three groups

    Hospital Anxiety and Depression Scale (HADS). Total score ranges from 0 to 42. Higher scores indicate greater anxiety and depression symptoms. Change from baseline in HADS scores will be compared among the three groups at Week 12 and Week 13.

    Time frame: 12th and 13th weeks

  10. Changes in Short Form-36 (SF-36) quality of life scale scores from baseline at 13 week after treatment in the three groups

    Short Form-36 (SF-36) quality of life scale. Each domain score ranges from 0 to 100. Higher scores indicate better quality of life. Change from baseline in SF-36 scores will be compared among the three groups at Week 13.

    Time frame: 13 week

  11. At the 13th week after treatment, the percentage of participants using emergency medication and the total amount of emergency medication in the three groups

    Time frame: 13th week

  12. The incidence of adverse reactions leading to drug withdrawal or reduction in drug dosage in each group

    Time frame: weekly

  13. Changes in SF-MPQ score and SF-MPQ-VAS score from baseline to the 52nd week after treatment

    Short-Form McGill Pain Questionnaire (SF-MPQ). Total score ranges from 0 to 45. Higher scores indicate worse pain. Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain.

    Time frame: 52 week

  14. During the drug withdrawal follow-up period, changes in weekly SF-MPQ scores compared to the baseline period

    Time frame: weekly

  15. Steady-state plasma concentration at 2 hours (C2h,ss) of YJ001

    Steady-state plasma concentration at 2 hours (C2h,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. C2h,ss will be measured at Weeks 21, 25 and 52.

    Time frame: weeks 21,25,52

  16. During the drug withdrawal follow-up period, changes in weekly SF-MPQ-VAS compared to the baseline period

    Time frame: weekly

  17. Steady-state plasma concentration at 6 hours (C2h,ss) of YJ001

    Steady-state plasma concentration at 6 hours (C6h,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. C6h,ss will be measured at Weeks 21, 25 and 52.

    Time frame: Weeks 21, 25 and 52

  18. Steady-state minimum plasma concentration (Cmin,ss) of YJ001

    Steady-state minimum plasma concentration (Cmin,ss) of YJ001 spray in patients with diabetic peripheral neuropathic pain. Cmin,ss will be measured at Weeks 21, 25 and 52.

    Time frame: Weeks 21, 25 and 52

07

Study locations

1 of 1 sites recruiting
  • Medical Institution
    Beijing, Haidian District 100089, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

Of 33 phase 3 interventional studies under Neuralgia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Oct 5, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07859111
Lead sponsor
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Aug 3, 2026
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Jing Zhang
Contact
zhangjing@zjhanmai.com
86-18602195085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YJ001

Start the discussion